These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7557658)

  • 1. In vitro characterization of antithrombin III concentrates--a single-blind study.
    Hellstern P; Moberg U; Ekblad M; Anders CU; Faller B; Müller S
    Haemostasis; 1995; 25(4):193-201. PubMed ID: 7557658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the heterogeneity of antithrombin III concentrates.
    Barrowcliffe TW; Eggleton CA; Mahmoud M
    Br J Haematol; 1983 Sep; 55(1):37-46. PubMed ID: 6882687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa.
    Izaguirre G; Olson ST
    J Biol Chem; 2006 May; 281(19):13424-13432. PubMed ID: 16517611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of monoclonal antibodies against the human thrombin-antithrombin III complex.
    Asakura S; Yoshida N; Matsuda M; Murayama H; Soe G
    Biochim Biophys Acta; 1988 Jan; 952(1):37-47. PubMed ID: 3422029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.
    Dementiev A; Swanson R; Roth R; Isetti G; Izaguirre G; Olson ST; Gettins PGW
    J Biol Chem; 2013 Nov; 288(47):33611-33619. PubMed ID: 24068708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex.
    Andersson LO; Engman L; Henningsson E
    J Immunol Methods; 1977; 14(3-4):271-81. PubMed ID: 557071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies of the turnover of dog antithrombin III. Study of 131I-labelled antithrombin protease complexes.
    Leonard B; Bies R; Carlson T; Reeve EB
    Thromb Res; 1983 Apr; 30(2):165-77. PubMed ID: 6868021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin.
    Marciniak E
    Br J Haematol; 1981 Jun; 48(2):325-36. PubMed ID: 7236529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the biological activity of antithrombin III in patients with hepatic cirrhosis.
    Matsuo T; Matsuo C; Matsuo O
    Clin Chim Acta; 1984 Jul; 140(2):125-32. PubMed ID: 6467606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pasteurisation induced changes in an antithrombin III concentrate.
    Winkelman L; Haddon ME
    Thromb Res; 1986 Jul; 43(2):219-27. PubMed ID: 3738862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities.
    De Stefano V; Leone G; Mastrangelo S; Lane DA; Girolami A; de Moerloose P; Sas G; Abildgaard U; Blajchman M; Rodeghiero F
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):7-15. PubMed ID: 8180341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-association of antithrombin III relates to multimer formation of thrombin-antithrombin III complexes.
    Preissner KT
    Thromb Haemost; 1993 May; 69(5):422-9. PubMed ID: 8322264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different prothrombin complex concentrates--in vitro and in vivo studies.
    Köhler M; Heiden M; Harbauer G; Miyashita C; Mörsdorf S; Braun B; Ernert P; Wenzel E; Rose S; Pindur G
    Thromb Res; 1990 Oct; 60(1):63-70. PubMed ID: 2148989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.